P
Peter C. Taylor
Researcher at University of Oxford
Publications - 397
Citations - 19020
Peter C. Taylor is an academic researcher from University of Oxford. The author has contributed to research in topics: Rheumatoid arthritis & Arthritis. The author has an hindex of 63, co-authored 359 publications receiving 16347 citations. Previous affiliations of Peter C. Taylor include HealthPartners & University of Cambridge.
Papers
More filters
Journal ArticleDOI
Contrast enhancement imaging in coronary arteries in SLE
Valentina O. Puntmann,David D'Cruz,Peter C. Taylor,Tarique Hussain,Andreas Indermühle,Britta Butzbach,René M. Botnar,Eike Nagel +7 more
TL;DR: Increased extracellular space in the coronary vessel wall can be visualized by contrast-enhanced inversion-recovery (CE-IR) prepared coronary by gadolinium enhancement imaging by cardiovascular magnetic resonance (CMR).
Journal ArticleDOI
Novel biomarkers of a peripheral blood interferon signature associated with drug-naïve early arthritis patients distinguish persistent from self-limiting disease course.
Attila A. Seyhan,Attila A. Seyhan,Bernard Gregory,Adam P. Cribbs,Sundeept Bhalara,Yizheng Li,Christine Loreth,Ying Zhang,Yongjing Guo,Lih-Ling Lin,Marc Feldmann,Lynn M. Williams,Fionula M. Brennan,Peter C. Taylor +13 more
TL;DR: In patients with early inflammatory arthritis, ST6GALNAC1 is a potential biomarker for UA as compared with healthy controls whereas EPHB2, MS4A4A, and particularly PDZK1IP1 may discriminate RA patients, and SIGLEC1 may also be a useful marker of disease activity in UA.
Journal ArticleDOI
Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: Results from a long-term study
Josef S Smolen,Li Xie,Bochao Jia,Peter C. Taylor,Gerd R Burmester,Yoshiya Tanaka,Ayesha Elias,Anabela Cardoso,Rob Ortmann,C. Walls,Maxime Dougados +10 more
TL;DR: Treatment with baricitinib 4 mg demonstrated efficacy for up to 3 years and was well tolerated and discontinuation rates were similar in the DMARD-naïve population.
Journal ArticleDOI
A naturalistic evaluation and audit database of agomelatine: clinical outcome at 12 weeks.
Anna Sparshatt,Anna Sparshatt,R. H. McAllister Williams,David S. Baldwin,Peter M. Haddad,Peter M. Haddad,S. Bazire,E. Weston,Peter C. Taylor,David Taylor,David Taylor +10 more
TL;DR: To determine the effectiveness of agomelatine in routine clinical practice and explore factors associated with response and continuation, a large number of patients are referred for treatment with this drug.
Journal ArticleDOI
A1.72 Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study1
Peter C. Taylor,Mark C. Genovese,E.C. Keystone,Douglas E Schlichting,Scott D. Beattie,William L. Macias +5 more
TL;DR: Clinical improvements observed at week 24 were maintained or improved during the open label extension of the phase 2b study, and safety signals observed over the openlabel extension were consistent with previously reported results of baricitinib.